Advanced Therapies Journal
Volume:6 Issue: 19, Spring 2024

The treatment landscape for advanced non-small cell lung cancer (NSCLC) has evolved significantly with the emergence of targeted therapies. Among these, tyrosine kinase inhibitors (TKIs) selective for the rearranged during transfection (RET) gene have shown promise. However, understanding resistance mechanisms and identifying effective treatments for patients progressing on RET-TKIs remains a challenge.

Case description: 

we present a patient with metastatic lung cancer harboring a fusion involving KIF5B-RET amplification. Notably, this patient did not receive Selpercatinib or Pralsetinib, two RET-selective TKIs commonly used in RET-positive NSCLC. Instead, the patient was successfully treated with Alectinib, highlighting the potential efficacy of this alternative therapy.

Our case report, provides a comprehensive overview of RET-positive advanced NSCLC, covering both therapeutic and molecular aspects. We compare clinical outcomes achieved with multikinase inhibitors (MKIs) and RET-selective TKIs, emphasizing the long-term resistance mechanisms. Additionally, we discuss unresolved issues and propose future pharmacological approaches.

Smoking is widely recognized as a significant factor in the global disease burden, leading to 4 million deaths annually throughout the globe. Various research has shown that the prevalence of smoking worldwide is on the rise among both males and females, particularly among the younger demographic. Behavior modification is a primary objective in public health initiatives that prioritises preventive measures before the occurrence of illness. Utilizing innovative personalized medicine programs may serve as a significant prognostic determinant in modifying the behavior of smokers and enhancing societal health. Thus, this review research presents an appropriate framework for personal medical applications that may effectively alter smokers' health and health behavior.

This paper discusses a comprehensive analysis of age differences in the manifestation of peripheral blood stem cells (PBSC) in individuals who have been diagnosed with COVID-19. The purpose of this research was to examine how age affects the body's response to the virus and identify factors that increase the likelihood of severe consequences in older people. By combining data from multiple studies, scientists compared levels of PBSC expression in younger and older individuals. The results showed that older individuals had higher levels of PBSC expression than their younger counterparts, highlighting the impact of age on the body's response to the virus. Additionally, a strong connection was found between increased PBSC expression levels and the severity of the disease, as well as poorer outcomes in older individuals. These findings suggest that levels of PBSC expression could be used as an important marker for monitoring the progression and seriousness of the disease in individuals with COVID-19, especially in older age groups. This analysis sheds light on age-related differences in PBSC expression among individuals affected by COVID-19 and underscores the crucial role played by age in understanding the body's response to the virus and identifying individuals at a higher risk of severe consequences. Future studies should delve deeper into the mechanisms behind these age-related variances and explore treatment strategies targeting PBSC expression in older individuals battling COVID-19.

Immunotherapies that use the immune system to eliminate tumor cells have shown substantial therapeutic effectiveness in several types of human malignancies. Several investigations have emphasized the importance of neoantigens in the recognition of cancer cells by innate T lymphocytes. The identification of neoantigens, which are altered proteins that are selectively produced in tumor cells and not in healthy cells, has resulted in the development of enhanced cancer vaccines. Neoantigen targeting may stimulate anti-tumor T-cell reactions to eliminate tumors while sparing healthy cells from harm. Significant progress in DNA sequencing and computational biology has enabled the identification and development of potent neoantigens for application as therapeutic cancer vaccines. Therapeutic customized vaccines that target neoantigens have demonstrated encouraging outcomes in the field of cancer therapy. Therefore, this study aims to introduce neoantigens and their use in cancer immunotherapy.

The World Health Organization's smallpox eradication program extensively utilized the Vaccinia virus, which is today regarded as a viable vector for gene therapy due to its distinctive features. Vaccinia virus can specifically reproduce and spread effectively in cancer cells, leading to the destruction of the tumor. Furthermore, the fast generation of viral particles, the ability to infect a wide variety of hosts, the big genome size (about 200 kb), and safe handling make the vaccinia virus an appropriate choice as a vector for gene therapies. Oncolytic virotherapy (OVT) is a highly prospective modality for fighting cancer that involves the use of genetically modified viruses to reproduce specifically inside cancer cells and stimulate an immune response against the tumor. Oncolytic viruses not only destroy cancer cells but may also modify the surrounding tumor microenvironment and trigger a durable defense against the tumor. Vaccinia virus has gained attention as a promising contender because of its capacity to invade a diverse array of cancer cells. In this study, we introduce the vaccinia virus, its molecular mechanism and cell cycle, and its potential to destroy cancer cells.

The CRISPR/Cas9 system has gained significant attention as a gene editing method in recent years because of its simple design, cost-effectiveness, high efficiency, and ease of use. Additionally, it allows for the simultaneous editing of many locations. Additionally, it may be performed without the use of plasmids, so avoiding the many complications associated with plasmids. CRISPR/Cas9 has shown significant promise in the investigation of genes and genomic activities in microbes, plants, animals, and humans. Transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) are genetic disorders characterized by severe and possibly life-threatening symptoms. In this article, we discuss the use of CRISPR/Cas9 technology in the treatment of these two diseases and FDA-approved drugs based on CRISPR/Cas9. In addition, we address the most important challenges of gene therapy using this technology.